NCT02260154

Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Effectiveness of Duspatalin® (Mebeverine Hydrochloride) 200 mg b.i.d. in Patients With Post-cholecystectomy Gastrointestinal Spasm: a Post Marketing Observational Program in the Russian Federation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 220 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg bis in die = twice a day (BID) and changes in quality of life in patients with post-cholecystectomy gastro-intestinal spasms

Conditions

• Post-cholecystectomy Gastrointestinal Spasms

Interventions

Type	Name	Description
DRUG	Mebeverine	Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed

Timeline

• Start date: 2015-07-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2014-10-09
• Last updated: 2019-06-06
• Results posted: 2019-06-06

Locations

21 sites across 1 country: Russia